Intertek Regulatory & Scientific Consultancy, 2233 Argentia Rd., Suite 201, Mississauga, ON, L5N 2X7, Canada.
Intertek Regulatory & Scientific Consultancy, 2233 Argentia Rd., Suite 201, Mississauga, ON, L5N 2X7, Canada.
Regul Toxicol Pharmacol. 2019 Apr;103:352-362. doi: 10.1016/j.yrtph.2019.01.033. Epub 2019 Feb 2.
Given the widespread use of the low-calorie sweetener aspartame over the last 30 years, the current work was undertaken to evaluate aspartame epidemiology studies looking at cancer endpoints against quality appraisal criteria. The quality appraisal tool used was from the National Heart, Lung and Blood Institute (NHLBI) of the National Institute of Health. Studies identified included nine case-control studies and five prospective cohort studies. Most studies assessed low-calorie or diet beverages rather than aspartame intake specifically; however, common use of aspartame in diet sodas does allow for some general extrapolation of results. Following consideration of study quality, two case-control and five prospective studies were considered to meet the majority of the NHLBI criteria. The primary limitation of the other case-control studies was an inadequate sample size. Overall, the results of the studies do not support that exposures to low and no-calorie sweeteners and beverages, and by extension aspartame, are associated with an increased risk of cancer in humans.
鉴于低卡路里甜味剂阿斯巴甜在过去 30 年中的广泛使用，目前开展了这项工作，以根据质量评估标准评估针对癌症终点的阿斯巴甜流行病学研究。使用的质量评估工具来自美国国立卫生研究院的国家心肺血液研究所 (NHLBI)。确定的研究包括九项病例对照研究和五项前瞻性队列研究。大多数研究评估的是低卡路里或饮食饮料，而不是专门评估阿斯巴甜的摄入量；然而，阿斯巴甜在无糖苏打水中的普遍使用确实允许对结果进行一些一般性推断。在考虑了研究质量之后，有两项病例对照研究和五项前瞻性研究被认为符合 NHLBI 的大多数标准。其他病例对照研究的主要局限性是样本量不足。总体而言，这些研究的结果并不支持低卡路里和无卡路里甜味剂和饮料（以及由此推断的阿斯巴甜）暴露与人类癌症风险增加之间存在关联。
